NorthWest Biotherapeutics Inc (NWBO)

[Chiugray]

Baxers, Great post again! Adding onto the many qualities DCVax has already (more holistic immune response, more effective, more personalized, less toxic, more preventative, and better outcomes), it will also save our healthcare systems and insurance companies money.

Over 2,100 doses of DCVax-L were administered during the Phase III trial and only 5 serious adverse events were possibly related to the treatment (none were classed as life threatening (Grade-4) or lead to Death (Grade-5). This is unprecedented and strongly suggests that supportive care costs will be substantially lower. Not to mention palliative care costs will be reduced as more patients are cured!